Clinical trials: Respiratory Distress
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Severe Eosinophilic Asthma, Psychological Distress
Severe Asthma, MepolizumaB and Affect: SAMBA Study
This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners.
- Conditions
- Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression
- Trial name
- SAMBA (NCT04680611)
- Testing
- no study intervention. Patients receive standard clinical care
- Where
- 6 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Corona Virus Infection, Acute Respiratory Distress Syndrome
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus
- Trial name
- COVID-19 PEP (NCT04308668)
- Testing
- Hydroxychloroquine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,312 people
- Sponsor
- University of Minnesota
Acute Lung Injury
Hemodynamics and Extravascular Lung Water in Acute Lung Injury
The purpose of this study is to test a treatment that tries to reduce the amount of fluid in the lungs of subjects with acute lung injury to see if this is helpful.
- Trial name
- HEAL (NCT00624650)
- Testing
- Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Oregon Health and Science University
Respiratory Distress Syndrome, Adult
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
This study will test the hypothesis that administration of granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) will improve the clinical…
- Trial name
- NCT00201409
- Testing
- GM-CSF
- Where
- 3 sites in United States
- Volunteers
- 132 people
- Sponsor
- University of Michigan
Corona Virus Infection, ARDS
Use of UC-MSCs for COVID-19 Patients
The purpose of this research study is to learn about the safety and efficacy of human umbilical cord derived Mesenchymal Stem Cells (UC-MSC) for treatment of COVID-19 Patients with Severe Complications of Acute Lung Injury/Acute…
- Conditions
- Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome
- Trial name
- NCT04355728
- Testing
- Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Camillo Ricordi
Acute Respiratory Distress Syndrome
KL₄Surfactant Treatment in Patients With ARDS
Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
- Trial name
- NCT00215553
- Testing
- A.1 Lucinactant, B.3 SoC, A.2 Lucinactant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Windtree Therapeutics
Transient Tachypnea of the Newborn
Fluid Management in Transient Tachypnea of the Newborn
Transient tachypnea of the newborn (TTN) is a diagnosis given to infants born between 34 and 42 weeks gestation who develop difficulty breathing during the first days of life when no specific cause of the breathing difficulty can…
- Trial name
- NCT01225029
- Testing
- Amount of total fluids
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Complication of Surgical Procedure, Acute Respiratory Failure, Adult
Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe
Prospective Evaluation of a RIsk Score for postoperative pulmonary COmPlications in Europe (PERISCOPE) is a multi-centre, international observational study of a random-sample cohort of patients undergoing a nonobstetric…
- Conditions
- Complication of Surgical Procedure, Acute Respiratory Failure, Adult, Postoperative Respiratory Complications, Pulmonary Failure
- Trial name
- PERISCOPE (NCT01346709)
- Where
- 63 sites in Albania, Belgium and 19 more
- Volunteers
- 5,450 people
- Sponsor
- European Society of Anaesthesiology
Respiratory Distress Syndrome
Premedication for Non-Emergency Endotracheal Intubation In the NICU
Those infants who received the muscle relaxation in combination with the vagolytic (reduce vagus nerve impulses) and pain medication will have reduced time to successful intubation (placement of tube into the lungs), a decrease…
- Trial name
- NCT01749501
- Testing
- Rocuronium
- Volunteers
- 45 people
- Sponsor
- Martin Espinosa, MD
Asthma
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
This study was a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when…
- Trial name
- NCT03052517
- Testing
- QAW039 150 mg, QAW039 450 mg
- Where
- 347 sites in United States, Argentina and 40 more
- Volunteers
- 2,538 people
- Sponsor
- Novartis Pharmaceuticals
Acute Respiratory Distress Syndrome
Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)
This study will be a multi-center, prospective, randomized, partially double-blind, placebo-controlled Phase II clinical trial of inhaled CO (iCO) for the treatment of ARDS.
- Trial name
- NCT03799874
- Testing
- Inhaled Carbon Monoxide at 200 ppm, Inhaled Medical air
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Brigham and Women's Hospital
Respiratory Distress Syndrome, Newborn, Premature Birth
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required…
- Conditions
- Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
- Trial name
- NCT00215540
- Testing
- Lucinactant 175 mg/kg, Lucinactant 90 mg/kg
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Windtree Therapeutics
Asthma
A Long-term Safety Study of QVM149 in Japanese Patients With Asthma
The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.
- Trial name
- NCT03100825
- Testing
- QVM149
- Where
- 25 sites in Japan
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Acute Respiratory Distress Syndrome
Nitric Oxide Administration for Acute Respiratory Distress Syndrome
This research project is an open-label, randomized study for the use of Nitric Oxide in pediatric patients with acute respiratory distress syndrome (ARDS).
- Trial name
- NCT00240487
- Testing
- Nitric Oxide, No Intervention
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Children's Hospital of Philadelphia
Asthma
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
- Trial name
- NCT03137784
- Testing
- NVA237 (glycopyrronium bromide)
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Deglutition Disorders, Respiratory Distress Syndrome In Premature Infants
Effect of Nasal Continuous Positive Airway Pressure on The Pharyngeal Swallow in Neonates
Oral feeding of neonates while on nasal continuous positive airway pressure (NCPAP) is a common practice in many neonatal intensive care units (NICU) all over the country.
- Conditions
- Deglutition Disorders, Respiratory Distress Syndrome In Premature Infants, Respiratory Aspiration, Newborn, Premature
- Trial name
- NCT02661256
- Testing
- NCPAP, Varibar® Thin Liquid Barium Sulfate for Suspension
- Volunteers
- 7 people
- Sponsor
- NYU Langone Health
Neonatal, Premature Birth
Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function
This is a study to see if an extra 2 weeks of continuous positive airway pressure (CPAP) in stable preterm infants in the neonatal intensive care unit (NICU) can cause increased lung growth and lung function in the infants as…
- Conditions
- Neonatal, Premature Birth, Respiratory Distress Syndrome
- Trial name
- NCT04295564
- Testing
- Additional 2 weeks of CPAP
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cynthia McEvoy
Acute Lung Injury, Acute Respiratory Distress Syndrome
Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
To evaluate whether administration of ganciclovir reduces serum IL-6 levels (i.e. reduction between baseline and 14 days post-randomization) in immunocompetent adults with severe sepsis or trauma associated respiratory failure.
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
- Trial name
- GRAIL (NCT01335932)
- Testing
- IV Ganciclovir
- Where
- 14 sites in United States
- Volunteers
- 160 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Respiratory Distress Syndrome
LIPS-A: Lung Injury Prevention Study With Aspirin
The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.
- Trial name
- NCT01504867
- Testing
- Aspirin, Lactose powder
- Where
- 16 sites in United States
- Volunteers
- 400 people
- Sponsor
- Mayo Clinic